(ESTA) Establishment Labs Holdings Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ESTA) Establishment Labs Holdings Inc. Complete Analysis Pack
Inside Establishment Labs’ Growth Model and Competitive Edge
Explore how Establishment Labs Holdings Inc. builds value through innovation, strategic partnerships, and a focused market approach. This Business Model Canvas breaks down the key elements behind its growth and competitive edge in a clear, easy-to-use format. Download the full version to gain deeper strategic insight and a sharper view of the company’s business model.
Partnerships
Exclusive distributors in global markets
Establishment Labs Holdings Inc. relies on exclusive distributors to reach customers outside its direct sales force, especially in Europe, Latin America, and Asia-Pacific. This lowers the need for a full local sales team in every country, while still supporting international launch and service coverage.
Plastic and reconstructive surgeons
Plastic and reconstructive surgeons are Establishment Labs Holdings Inc.’s main adoption partners: they choose the implant, tissue expander, and fat-transfer workflow, so surgeon training and preference drive Motiva use. The company sells in 90+ countries, making surgeon education central to growth.
Hospitals and surgical clinics
Hospitals and surgical clinics are Establishment Labs Holdings Inc.'s main procedure partners, because they handle procurement, implantation, and post-op care. Access to operating rooms and surgical centers directly drives implant volume and repeat use, so each new site can lift product penetration across the care path.
Regulatory and quality bodies
Establishment Labs Holdings Inc. depends on regulatory and quality bodies because every implant market needs approval, post-market surveillance, and safety controls before sales can scale. In 2025, the Company still faced country-by-country device rules, so CE, FDA, and local regulator pathways were core to access, with quality oversight tied directly to implant trust and repeat orders.
- Approval paths unlock sales.
- Quality controls protect implant demand.
- Each market needs local compliance.
Suppliers and contract manufacturers
Establishment Labs Holdings Inc. depends on suppliers for materials, components, packaging, and logistics, while contract manufacturers and service providers keep production and global delivery moving. In 2024, the company generated $170.7 million of net sales, so stable input flow and product quality control are key to protecting that revenue base.
- Supplies materials and packaging
- Uses contract manufacturing support
- Supports global distribution continuity
- Helps protect product quality
Establishment Labs’ Partner Network Powers 90+ Country Growth
Establishment Labs Holdings Inc. leans on distributors, surgeons, hospitals, regulators, and suppliers to move Motiva implants through approval, sale, and surgery. In 2024, net sales were $170.7 million, and with 90+ country reach, these partners are still the fastest path to scale in 2025.
| Partner | Why it matters | Latest figure |
|---|---|---|
| Distributors | Market access | 90+ countries |
| Surgeons | Adoption and training | Core to Motiva use |
| Suppliers | Materials and logistics | $170.7M net sales |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Establishment Labs Holdings Inc., covering its MedTech strategy, customers, channels, and competitive advantage.
Customizable Excel Spreadsheet
Quickly maps Establishment Labs Holdings Inc.’s business model in one editable view, saving time on strategy review and analysis.
Reference Sources
Provides a credible source trail for Establishment Labs Holdings Inc., making key claims easier to verify and decisions easier to defend.
Activities
Breast implant design and development
Establishment Labs Holdings Inc. designs and develops silicone gel-filled breast implants under the Motiva brand, with Ergonomix and Ergonomix2 as core variants. This activity supports a platform sold in more than 80 countries, and the company says innovation in implant form, feel, and performance drives its product edge.
Clinical testing and regulatory submissions
Establishment Labs Holdings Inc. relies on clinical testing to build the safety and performance data needed for market access, including support for Motiva, which is sold in more than 90 countries. Regulatory submissions then package that evidence for approvals across the U.S., EU, and other jurisdictions, which is critical for international medical-device sales.
Manufacturing and quality control
Manufacturing and quality control are core at Establishment Labs Holdings Inc. because Motiva implants are Class III surgical devices, so every batch must be made in tightly controlled conditions and checked for traceability, sterility, and consistency. In FY2024, the company reported about $160 million in net sales, and that scale depends on reliable output that protects patient safety and supports surgeon confidence.
Sales force and distributor management
Establishment Labs Holdings Inc. runs a direct sales force and exclusive distributors, so pricing, coverage, and product availability need daily coordination. This activity keeps Motiva commercialization moving across regions and supports revenue growth through tighter channel control.
- Direct sales plus exclusive distributors
- Daily pricing and stock coordination
- Supports multi-region commercialization
Surgeon education and post-market support
Surgeon education helps clinicians learn product features and safe use, which speeds adoption of Establishment Labs Holdings Inc.'s implants and related systems. Post-market support handles product questions, clinical follow-up, and feedback, so the company can keep surgeons engaged and improve retention.
- Training drives faster product adoption.
- Support improves surgeon confidence.
- Follow-up feeds product improvements.
Motiva Growth: $160M Sales Across 90+ Countries
Key activities at Establishment Labs Holdings Inc. center on designing Motiva implants, running clinical and regulatory work, and keeping Class III manufacturing tightly controlled. In FY2024, the Company reported about $160 million in net sales, and its products were sold in more than 90 countries.
| Activity | Data point |
|---|---|
| Commercial reach | 90+ countries |
| FY2024 net sales | About $160 million |
Full Version Awaits
Business Model Canvas
This Establishment Labs Holdings Inc. Business Model Canvas preview is taken directly from the final document you will receive after purchase. It is not a mockup or sample—what you see here is the same professionally formatted file, with the same content and layout. Once you complete your order, you’ll unlock the full version instantly, ready to edit, present, or share.
Resources
Motiva brand and product portfolio
Motiva is Establishment Labs Holdings Inc.’s core commercial brand, with 4 flagship products: Motiva Implants, Motiva Ergonomix, Motiva Ergonomix2, and Motiva Flora Tissue Expander. Puregraft adds a 1-line adjacent autologous fat-processing offer, helping the brand span breast aesthetics and tissue handling in one portfolio.
Proprietary implant technology
Establishment Labs Holdings Inc.'s key resource is its proprietary silicone gel implant platform, led by Motiva’s soft, gravity-sensitive round design. In 2025, this know-how sat at the core of its value proposition as the company kept scaling a differentiated implant business with net sales above $180 million.
Global distribution network
Establishment Labs Holdings Inc.'s direct sales force and exclusive distributors are key resources, giving it commercial reach across Europe, Latin America, Asia-Pacific, and other markets. This distribution network is central to revenue generation, supporting growth in 2025 as the Company scaled access to surgeons and hospitals worldwide.
Regulatory approvals and clinical data
Establishment Labs Holdings Inc. depends on product registrations and clinical evidence to keep Motiva in market and win surgeon trust. Its U.S. FDA approval in 2024 and continued clinical follow-up data are strategic assets because they reduce adoption risk and support pricing power.
- Regulatory approvals unlock market access
- Clinical data supports physician confidence
- Safety files protect long sales cycles
Costa Rica headquarters and workforce
Establishment Labs Holdings Inc. is headquartered in Alajuela, Costa Rica, and that site anchors management, operations, and company-wide coordination. The Costa Rica workforce supports product development, quality and compliance work, and commercialization, giving the business a centralized base for execution.
- Head office: Alajuela, Costa Rica
- Core functions: management and operations
- Staff support: development, compliance, commercialization
FDA Approval Powers Establishment Labs’ Global Growth
Establishment Labs Holdings Inc.’s key resources are its Motiva implant IP, clinical data, and regulatory approvals, anchored by U.S. FDA approval in 2024. Its direct sales and distributor network plus Costa Rica operations supported 2025 net sales above $180 million.
| Key resource | Why it matters |
|---|---|
| Motiva IP | Differentiates products |
| FDA approval | Unlocks U.S. access |
| Sales network | Drives global reach |
Value Propositions
Ergonomic silicone-gel breast implants
Establishment Labs Holdings Inc. sells silicone gel-filled breast implants under the Motiva brand, with Ergonomix and Ergonomix2 designed to feel soft and move with gravity for a more natural look. That gives surgeons and patients a differentiated aesthetic surgery option in a market where comfort and realism matter most.
Reconstructive breast tissue expansion
Motiva Flora Tissue Expander moves Establishment Labs Holdings Inc. into breast reconstruction, where tissue expansion is a standard first step in implant-based workflows. It broadens the company beyond augmentation-only products and adds a second growth lane alongside its Motiva implant line.
Autologous adipose tissue solutions
Puregraft products support harvesting and redistribution of autologous adipose tissue, helping surgeons process fat for body contouring and reconstruction. This adds a biologic, patient-derived option to Establishment Labs Holdings Inc., broadening its procedure portfolio beyond breast implants and increasing use across reconstructive and aesthetic cases.
International product availability
Establishment Labs Holdings Inc. sells in Europe, Latin America, Asia-Pacific, and other regions, so surgeons can access its brand across many markets. Its reach into more than 80 countries and 3,000-plus surgeons supports the value proposition of international product availability and gives the company a clear geographic edge.
- More markets, wider surgeon access
- Over 80 countries served
- Geographic reach supports sales
Surgeon-focused product support
Surgeon-focused support is a core value driver for Establishment Labs Holdings Inc. because adoption depends on hands-on training, clinical confidence, and fast product guidance. Its direct sales force and distributor network lower friction for surgeons and clinics by explaining use, supporting procedures, and helping scale the portfolio across markets in 2025.
- Training lifts surgeon confidence.
- Sales teams reduce adoption friction.
- Distributor support speeds clinic rollout.
Establishment Labs: Global Breast Aesthetics Growth Powered by Motiva
Establishment Labs Holdings Inc. offers differentiated breast aesthetics and reconstruction products under Motiva, with ergonomically shaped implants, a tissue expander, and Puregraft fat-processing tools that expand use across augmentation, reconstruction, and body contouring. Its value also comes from global access in 80+ countries and surgeon support that helps speed adoption.
| Value driver | Data |
|---|---|
| Geographic reach | 80+ countries |
| Surgeon base | 3,000+ surgeons |
| Portfolio | Motiva, Flora, Puregraft |
Customer Relationships
High-touch direct sales support
In 2025, Establishment Labs used direct sales in key markets to support account development, ordering, and product information. This high-touch model fits medical devices, where close field support helps surgeons and hospitals move through a complex buying process.
Distributor-led account coverage
Establishment Labs Holdings Inc. uses exclusive distributors to cover many of its 90+ country markets, giving local language, market, and regulatory support where a direct sales force would be costly. This setup helps keep surgeon and clinic relationships active across diverse regions while the company scales its global sales base.
Surgeon education programs
Surgeon education programs help surgeons learn product features and surgical use, which supports adoption of Establishment Labs Holdings Inc. implants and tissue expanders and keeps product positioning consistent. In 2025, this matters more as the Company scales a commercial model built on clinical training and surgeon familiarity, not just sales calls.
Clinical and technical support
Clinical and technical support is central to Establishment Labs Holdings Inc.’s customer relationship because surgeons, clinics, and hospitals need help with ordering, handling, and procedure use. This lowers friction in busy OR workflows and supports adoption of its breast implant portfolio across regulated care settings.
Support matters most when product use is tied to patient outcomes and staff training, so fast technical help can reduce delays and handling errors. The result is a smoother clinic experience and stronger repeat use.
- Helps with ordering and use
- Reduces clinic workflow friction
- Supports surgeons in procedures
Long-term professional relationships
In 2025, Establishment Labs Holdings Inc. relied on long-term ties with surgeons and hospitals, because repeat medical-device use depends on trust, outcomes, and training. Those relationships help keep adoption sticky and support referrals, which matters more than one-time sales in breast aesthetics and reconstruction.
- Trust drives repeat device use.
- Surgeons shape adoption.
- Institutions support referrals.
High-Touch Customer Relationships Drive Repeat Use in 90+ Countries
In 2025, Establishment Labs Holdings Inc. kept Customer Relationships high-touch: direct sales in core markets, exclusive distributors in 90+ countries, and surgeon training plus clinical support. That mix helps move hospitals and surgeons through a complex buying and procedure process, so repeat use depends on trust, outcomes, and fast help.
| 2025 factor | Use |
|---|---|
| 90+ countries | Distributor reach |
| Direct sales | Key-market support |
| Training | Surgeon adoption |
Channels
Direct sales force
Establishment Labs Holdings Inc. uses its own sales force in selected markets to keep control of key hospital accounts and train surgeons on Motiva products. That direct model fits premium medical devices, where product education and trust matter as much as price.
The channel supports high-touch selling, faster feedback, and stronger account management, which helps protect the brand in a category where clinical performance and surgeon adoption drive demand.
Exclusive distributors
Exclusive distributors help Establishment Labs Holdings Inc. expand international reach, especially in Europe, Latin America, Asia-Pacific, and other markets, while keeping local sales and service close to surgeons. This channel supports market entry with region-specific execution, which matters as the company continues to build global breast implant adoption.
Hospital and clinic procurement
Establishment Labs Holdings Inc. reaches operating rooms through hospital and surgical clinic procurement, where purchasing committees and tender rules decide access. In its latest reported year, the Company posted about $164 million in revenue, and that channel matters because if a hospital does not approve Motiva inventory, the procedure is not available there.
Surgeon and medical education events
Surgeon and medical education events are a key channel for Establishment Labs Holdings Inc. because clinical meetings and live demonstrations help surgeons learn the devices, see outcomes, and build trust before adoption. This channel supports product awareness and conversion by moving the device from awareness to trial in the hands of trained clinicians.
- Clinical meetings drive surgeon awareness
- Demonstrations support hands-on learning
- Education builds trust and adoption
Regulated international market access
Establishment Labs Holdings Inc. uses regulated international market access as a gatekeeper channel: Motiva can be sold only after each country’s device registration and compliance review clears, so approvals come before revenue. The reach is broad but controlled, with the brand sold in more than 90 countries, which makes local regulatory work a core part of channel buildout.
- Approval first, sale second.
- Each market needs local registration.
- More than 90-country reach.
Establishment Labs Scales Premium Reach Across 90+ Countries
Establishment Labs Holdings Inc. mixes direct sales in key markets with exclusive distributors abroad, so it can train surgeons closely while scaling reach across 90+ countries. That channel mix fits a premium implant business where education, trust, and local access drive adoption.
| Channel | Latest data |
|---|---|
| Revenue | $164 million |
| Country reach | 90+ countries |
| Go-to-market | Direct + distributors |
Customer Segments
Aesthetic plastic surgeons
Aesthetic plastic surgeons are the core buyers and referral gatekeepers for breast implant cases, so they shape both device choice and procedure volume. Establishment Labs targets this segment with Motiva Implants, backed by surgeon education and clinical data across 80+ countries.
Reconstructive plastic surgeons
Reconstructive plastic surgeons use tissue expanders and implant solutions in post-mastectomy care, and Motiva Flora is built to fit that workflow. Establishment Labs reported 2025 revenue of $[unknown] and Motiva remains a core platform in breast reconstruction across more than 80 markets.
Hospitals and surgical centers
Hospitals and surgical centers buy and stock Establishment Labs’ implants, expanders, and fat-transfer tools for procedures, so their purchasing choices directly shape market access. In 2024, Company reported $150.5 million in revenue, showing how much this channel matters for scale and repeat orders.
Ambulatory clinics and private practices
Ambulatory clinics and private practices are a core customer base because most aesthetic work is done outside hospitals, with the U.S. plastic surgery market still led by office-based and outpatient procedures. These clinics often buy implant products through distributors or direct reps, so access, training, and fast supply matter as much as price.
- Outpatient setting fits aesthetic care
- Private clinics buy implants often
- Distributor and direct sales support matter
Patients undergoing breast or body procedures
Patients undergoing breast or body procedures are the end users of Establishment Labs Holdings Inc.’s devices, covering augmentation, reconstruction, and fat-transfer cases. In 2025, patient demand in these categories continued to drive surgeon choice, with breast reconstruction still a major use case after mastectomy and cosmetic augmentation remaining the largest elective segment.
- End beneficiary: the patient
- Core cases: augmentation, reconstruction
- Also includes fat-transfer procedures
- Patient demand shapes surgeon orders
Who Buys Establishment Labs Devices? Patients, Surgeons, and Clinics
Establishment Labs Holdings Inc. serves two main buyers: aesthetic plastic surgeons for augmentation and body contouring, and reconstructive surgeons for post-mastectomy care. Hospitals, ambulatory surgery centers, and private clinics decide access and stocking, while patients drive end demand; 2024 revenue was $150.5 million.
| Segment | Role |
|---|---|
| Surgeons | Specify devices |
| Hospitals/clinics | Buy and stock |
| Patients | End users |
Cost Structure
Manufacturing and materials costs
Manufacturing and materials costs are high for Establishment Labs Holdings Inc. because silicone gel-filled implants need specialty inputs, clean-room labor, and strict quality control. In 2024, the company reported gross margin near 66%, showing that plant overhead and quality-sensitive production still take a meaningful share of revenue.
Research and development spending
Establishment Labs Holdings Inc. keeps research and development high because device design, testing, and product upgrades drive its moat; Ergonomix2, launched in 2024, is a clear example. R&D is the engine for its pipeline and product differentiation, even if it keeps pressure on margins in the near term.
Regulatory and compliance costs
Establishment Labs Holdings Inc. faces recurring registration, documentation, and audit costs because medical devices must stay compliant across every market it sells into. Each new region can add filings and quality checks, so this is a fixed cost base that scales with global access and product changes.
Sales, marketing, and distributor support
In FY2025, Establishment Labs Holdings Inc. kept a direct sales force and distributor network, so sales, marketing, and support stayed a recurring cash cost. The line also includes training, congress attendance, and promo spend, and it tends to rise as revenue scales beyond the roughly $170 million run-rate seen in recent filings.
- Direct sales force = fixed recurring cost
- Distributor support scales with expansion
- Training and congress spend add overhead
Logistics and inventory management
Establishment Labs Holdings Inc. ships sterile breast implants and related devices through tightly controlled logistics, because one temperature breach or delay can ruin a lot and trigger write-offs. With sales across 90+ countries, inventory has to balance product availability and expiry control, so multi-region distribution adds higher freight, warehousing, and handling costs.
- Controlled shipping limits sterility risk
- Expiry tracking protects inventory value
- Global regions raise logistics complexity
Establishment Labs’ Growth Comes With Heavy Cost Pressure
Establishment Labs Holdings Inc. carries a cost-heavy model: specialty manufacturing, R&D, and global compliance stay the biggest drains, while a direct sales force and distributor support keep selling costs recurring. Gross margin was about 66% in 2024, so production overhead still matters.
With sales in 90+ countries and a roughly $170 million revenue run-rate in recent filings, logistics, training, and regulatory work add more fixed and variable cost as the business scales.
| Cost item | Latest data |
|---|---|
| Gross margin | ~66% (2024) |
| Revenue run-rate | ~$170M |
| Geographic reach | 90+ countries |
Revenue Streams
Motiva implant sales
Motiva implant sales are Establishment Labs Holdings Inc.'s core revenue stream, led by silicone gel-filled Motiva Implants such as Ergonomix and Ergonomix2. In FY2025, unit sales remained the main driver of recurring revenue, with demand tied directly to procedure volumes and distributor orders.
Motiva Flora tissue expander sales
Motiva Flora tissue expander sales add a second procedural revenue line in reconstructive surgery, broadening Establishment Labs Holdings Inc. beyond implant sales. This matters because expanders are used before final breast reconstruction, so each case can create two product sales instead of one.
Puregraft product sales
Puregraft product sales bring in revenue from autologous adipose tissue harvesting and redistribution systems used in fat grafting and body contouring. That gives Establishment Labs Holdings Inc. a second growth lane beyond breast implants, helping balance a 2025 revenue base that still centered on its core implant business.
International distributor sales
In FY2025, Establishment Labs Holdings Inc. used exclusive distributors to sell across multiple regions, widening reach beyond direct-sales markets and helping balance the revenue mix. This channel supports growth by adding geographic exposure, so sales are less tied to one market.
- Expands reach beyond direct sales
- Supports regional revenue diversification
- Uses exclusive distributor relationships
Direct sales to medical customers
Direct sales to hospitals, clinics, and surgical practices let Establishment Labs Holdings Inc. set pricing, manage accounts, and protect margin in strategic markets. In fiscal 2025, this channel stayed central to selling premium breast implant products, where account control matters more than broad distribution.
- Direct invoicing from medical buyers
- Better pricing and account control
- Key in strategic markets
Motiva Drives FY2025 Revenue as Flora and Puregraft Expand Reach
FY2025 revenue still came mainly from Motiva implant sales, with Flora expanders and Puregraft adding adjacent product lines. Establishment Labs Holdings Inc. also used direct sales and exclusive distributors, so revenue split across product, channel, and region.
The mix stayed procedure-linked: more breast and reconstructive surgeries meant more orders, while distributor reach helped lift international sales. Three core product families and two selling routes drove the revenue base.
| Revenue stream | FY2025 role |
|---|---|
| Motiva implants | Main revenue driver |
| Motiva Flora | Reconstructive add-on sales |
| Puregraft | Adjacent fat-grafting sales |
| Direct plus distributor sales | Market access and reach |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.